Document Detail

Effect of allopurinol in decreasing proteinuria in type 2 diabetic patients.
MedLine Citation:
PMID:  20404423     Owner:  NLM     Status:  MEDLINE    
INTRODUCTION: Diabetic nephropathy is the most prevalent cause of end-stage renal disease. Besides factors such as angiotensin II, cytokines, and vascular endothelial growth factor, uric acid may play a role as the underlying cause of diabetic nephropathy. We evaluated allopurinol effects on proteinuria in diabetic patients with nephropathy.
MATERIALS AND METHODS: In a double-blinded randomized controlled trial on 40 patients with type 2 diabetes mellitus and diabetic nephropathy (proteinuria, at least 500 mg/24 h and a serum creatinine level less than 3 mg/dL), allopurinol (100 mg/d) was compared with placebo. Administration of antihypertensive and renoprotective drugs (angiotensin-converting enzyme inhibitors and angiotensin receptor blockers continued for both groups, without changes in dosage. Proteinuria was compared at baseline and 2 and 4 months between the two groups.
RESULTS: Each group consisted of 9 men and 11 women. There were no difference between two groups regarding age, body mass index, duration of diabetes mellitus, systolic and diastolic blood pressure, fasting blood glucose, blood urea nitrogen, serum creatinine, serum potassium, and urine volume. Serum levels of uric acid (P = .02) and 24-hour urine protein (P = .049) were significantly lower in the patients on allopurinol, after 4 months of receiving allopurinol, compared with the control group.
CONCLUSIONS: Low-dose allopurinol can reduce severity of proteinuria after 4 months of drug administration, which is probably due to decreasing the serum level of uric acid. Thus, allopurinol can be administered as an adjuvant cost-effective therapy for patients with diabetic nephropathy.
Ali Momeni; Shahrzad Shahidi; Shiva Seirafian; Shahram Taheri; Soleiman Kheiri
Related Documents :
2976763 - Diabetic cystopathy--a risk factor in diabetic nephropathy?
10900293 - Vascular endothelial markers, von willebrand factor and thrombomodulin index, are speci...
9661973 - Clinical and stabilometric monitoring in a case of cerebellar atrophy with vitamin e de...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Iranian journal of kidney diseases     Volume:  4     ISSN:  1735-8582     ISO Abbreviation:  Iran J Kidney Dis     Publication Date:  2010 Apr 
Date Detail:
Created Date:  2010-04-20     Completed Date:  2010-11-30     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101316967     Medline TA:  Iran J Kidney Dis     Country:  Iran    
Other Details:
Languages:  eng     Pagination:  128-32     Citation Subset:  IM    
Division of Nephrology, Department of Internal Medicine, Hajar Hospital, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Allopurinol / therapeutic use*
Diabetes Mellitus, Type 2 / complications*
Diabetic Nephropathies / drug therapy*
Double-Blind Method
Gout Suppressants / therapeutic use*
Middle Aged
Proteinuria / drug therapy*,  etiology
Reg. No./Substance:
0/Gout Suppressants; 315-30-0/Allopurinol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Renal involvement in patients with hepatitis C virus infection.
Next Document:  Hematuria in patients with Beta-thalassemia major.